{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:56:14Z","timestamp":1765886174375,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Capital Special Foundation of Clinical Application Research","award":["Z121107001012015"],"award-info":[{"award-number":["Z121107001012015"]}]},{"name":"Capital Health Development Fund","award":["201614035"],"award-info":[{"award-number":["201614035"]}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7131014"],"award-info":[{"award-number":["7131014"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Major Collaborative Innovation Project","award":["2016-I2M-1-011"],"award-info":[{"award-number":["2016-I2M-1-011"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.prostaglandins.2019.106345","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:55:23Z","timestamp":1562158523000},"page":"106345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease"],"prefix":"10.1016","volume":"144","author":[{"given":"Xi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2019.106345_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/jhh.2009.34","article-title":"Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study","volume":"24","author":"Blacher","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive loweringof LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(80)90280-9","article-title":"Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death","volume":"2","author":"Keys","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/clpt.2014.79","article-title":"High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm","volume":"96","author":"Tuteja","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0025","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1210\/jc.2009-0344","article-title":"Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma","volume":"94","author":"Fazio","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.atherosclerosis.2009.01.044","article-title":"HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study","volume":"206","author":"Arsenault","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jacl.2012.03.001","article-title":"High-density lipoprotein subclasses and their relationship to cardiovascular disease","volume":"6","author":"Superko","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0045","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1097\/MD.0000000000002600","article-title":"Large HDL subfraction but not HDL-C is closely linked with risk factors, coronary severity and outcomes in a cohort of nontreated patients with stable coronary artery disease: a prospective observational study","volume":"95","author":"Li","year":"2016","journal-title":"Medcine"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.104.529297","article-title":"Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-age men from the general population","volume":"112","author":"Meisinger","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0055","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.ATV.20.10.2243","article-title":"Circulating oxidized-lowdensity lipoprotein levels: a biochemical risk marker for coronary heart disease","volume":"20","author":"Toshima","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2019.106345_sbref0060a","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2796.2004.01402.x","article-title":"Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men","volume":"56","author":"Wallenfeldt","year":"2004","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.prostaglandins.2019.106345_sbref0060b","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.CIR.95.4.1062","article-title":"Conner memorial lecture: oxidative modification of LDL and atherosclerosis","volume":"95","author":"Steinberg","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clinbiochem.2012.02.022","article-title":"Association among retinol-binding protein 4, small dense LDL cholesterol and oxidized LDL levels in dyslipidemia subjects","volume":"45","author":"Wu","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0070","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jacl.2015.08.010","article-title":"Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease","volume":"9","author":"Zhu","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.plipres.2012.03.003","article-title":"Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?","volume":"51","author":"Otocka-Kmiecik","year":"2012","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.beem.2013.11.001","article-title":"Emerging therapies for raising highdensity lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality","volume":"28","author":"Barylski","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0090","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and highdensity lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.10.018","article-title":"HDL functionality in type 1 diabetes","volume":"267","author":"Ganjali","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2014.10.030","article-title":"Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury follpwing percutaneous coronary intervention in type 2 diabetes","volume":"237","author":"Zeng","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2014.10.030","article-title":"Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury follpwing percutaneous coronary intervention in type 2 diabetes","volume":"237","author":"Zeng","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0110","first-page":"844","article-title":"Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients","volume":"12","author":"Rysz-G\u00f3rzy\u0144ska","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0115","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/0929867321666140414103455","article-title":"Subfractions and subpopulations of HDL: an update","volume":"21","author":"Rizzo","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.CIR.84.1.129","article-title":"HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men","volume":"84","author":"Salonen","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0125","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/01.ATV.17.6.1098","article-title":"Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Que\u00b4bec Cardiovascular Study","volume":"17","author":"Lamarche","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/01.ATV.16.5.697","article-title":"Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression","volume":"16","author":"Mack","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0135","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/01.ATV.0000091338.93223.E8","article-title":"Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress","volume":"23","author":"Kontush","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0140","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0145","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MAJ.0000000000000231","article-title":"High-density lipoprotein functionality in coronary artery disease","volume":"347","author":"Kosmas","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0150","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/CIRCULATIONAHA.111.073684","article-title":"Lipids and lipoproteins and risk of different vascular events in the MRC\/BHF Heart Protection Study","volume":"125","author":"Parish","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0155","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0160","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.ATV.21.5.844","article-title":"Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease","volume":"21","author":"Holvoet","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0165","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2005.05.020","article-title":"Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques","volume":"185","author":"Anselmi","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0170","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.103.15.1955","article-title":"Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes","volume":"103","author":"Ehara","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2005.11.006","article-title":"Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease","volume":"113","author":"Johnston","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.prostaglandins.2019.106345_bib0180","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/nu5030928","article-title":"Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches","volume":"5","author":"Nikolic","year":"2013","journal-title":"Nutrients"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882318301588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882318301588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:59:47Z","timestamp":1761098387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882318301588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"alternative-id":["S1098882318301588"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106345","relation":{},"ISSN":["1098-8823"],"issn-type":[{"type":"print","value":"1098-8823"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106345"}}